Creating a platform to personalize therapy for patients with multiple myeloma
Development of a multi-omic clinical decision platform to guide personalized therapy
This study is working on a new tool to help doctors create personalized treatment plans for people with multiple myeloma by using advanced genetic testing and technology to better understand the disease and find the best therapies for each patient.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10814815 on NIH RePORTER |
What this research studies
This research focuses on developing a clinical decision platform that utilizes advanced genomic and systems biology techniques to improve treatment options for patients with multiple myeloma, a type of cancer affecting the bone marrow. By combining high-throughput profiling technologies with machine learning, the project aims to generate predictive tools that can enhance disease forecasting and tailor treatment plans. The approach includes targeted sequencing and RNA-sequencing to better understand the disease and identify potential new therapies. Patients will benefit from a more personalized approach to their treatment based on their unique genetic and biological profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple myeloma who are seeking advanced treatment options.
Not a fit: Patients with other types of cancer or those not diagnosed with multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with multiple myeloma.
How similar studies have performed: Other research has shown promise in using genomic data and machine learning to improve treatment outcomes in cancer, indicating that this approach has potential for success.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Parekh, Samir — Icahn School of Medicine at Mount Sinai
- Study coordinator: Parekh, Samir
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.